Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2009 Financial Results on Wednesday, February 11th, at 4:30 P.M. EST

    TORONTO, Feb. 9 /CNW/ - Transition Therapeutics Inc. ("Transition" or the
"Company") (NASDAQ:   TTHI, TSX: TTH) will hold a conference call on Wednesday,
February 11, 2009 at 4:30 P.M. EST to discuss the Second Quarter fiscal 2009
financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the
Company, will host the call. Transition will announce its financial results
for this period in a press release to be issued prior to the call. In order to
participate in the conference call, please call 1(800) 771-6781 (North
America), 1(212) 231-2901 (International). A replay of the conference call
will be available on Transition's website for
seven days following the call.

    About Transition

    Transition is a biopharmaceutical company, developing novel therapeutics
for disease indications with large markets. Transition's lead products include
ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the
treatment of diabetes. Transition has an emerging pipeline of preclinical drug
candidates acquired externally and developed internally using its proprietary
drug discovery engine. Transition's shares are listed on the NASDAQ under the
symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For
additional information about the Company, please visit

    Notice to Readers: Information contained in our press releases should be
considered accurate only as of the date of the release and may be superseded
by more recent information we have disclosed in later press releases, filings
with the OSC, SEC or otherwise. Except for historical information, this press
release may contain forward-looking statements, relating to expectations,
plans or prospects for Transition, including conducting clinical trials and
potential efficacy of its products. These statements are based upon the
current expectations and beliefs of Transition's management and are subject to
certain risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. These risks
and uncertainties include factors beyond Transition's control and the risk
factors and other cautionary statements discussed in Transition's quarterly
and annual filings with the Canadian commissions.

    %SEDAR: 00015806E

For further information:

For further information: on Transition, visit or contact: Dr. Tony Cruz, Chief Executive
Officer, Transition Therapeutics Inc, Phone: (416) 260-7770, x.223,; Mr. Elie Farah, President and CFO,
Transition Therapeutics Inc., Phone: (416) 260-7770, x.203,

Organization Profile

Transition Therapeutics Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890